GLP-1 side effects follow a pattern so predictable you can almost set a calendar by it. These drugs — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) — slow your stomach and quiet appetite signals, and the same mechanism that drives weight loss also drives nausea. Per the Wegovy prescribing information, about 44% of patients reported nausea in trials. The good news: most symptoms are mild, cluster around dose increases, and fade as your body adjusts. The important news: a short list of rare problems — pancreatitis, gallbladder attacks, kidney injury — is never normal. Here is how to tell the two apart.
GLP-1 Side Effects by the Numbers
The best frequency data comes from the placebo-controlled trials behind Wegovy’s FDA approval, because thousands of people took the exact 2.4 mg weekly dose that telehealth programs prescribe today. The table below shows every side effect reported by at least roughly 1 in 10 patients, per the Wegovy prescribing information.
| Side effect | Wegovy 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 10% |
| Headache | 14% | 12% |
| Fatigue | 11% | 5% |
Two things stand out. First, stomach effects dominate — the top four are all digestive. Second, the placebo columns are not zero, which is a useful reality check: some of what people blame on the drug is just life.
Severity matters more than frequency. In the STEP 1 trial, published in the New England Journal of Medicine, gastrointestinal problems were the most common adverse events but were typically transient and mild to moderate. Only about 4.5% of semaglutide participants stopped treatment because of them, versus 0.8% on placebo — and the group still lost an average of 14.9% of body weight over 68 weeks.
Tirzepatide tells a similar story. In the SURMOUNT-1 trial, nausea affected roughly 25% to 33% of participants depending on dose, mostly mild to moderate and mostly during dose escalation, while average weight loss reached up to 20.9% over 72 weeks at the highest dose.
Why the Nausea Happens — and When It Peaks
Per the Cleveland Clinic, GLP-1 agonists copy a gut hormone that slows how fast your stomach empties and tells your brain you are full. Slower stomach emptying is the point — it is a big part of why you eat less. It is also why a normal-sized meal can suddenly sit like a brick.
That is why side effects track the dose schedule so closely. Per the Wegovy prescribing information, the dose steps up about every 4 weeks — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then the 2.4 mg maintenance dose — a ramp of roughly 16 weeks designed specifically to let your gut adapt. Symptoms typically flare in the days after each increase, then settle. Tirzepatide follows the same logic, climbing from 2.5 mg toward 15 mg in 4-week steps.
Practically, that means the first 4 to 5 months are the bumpy part. If week 6 feels worse than week 4, check your calendar — you probably just moved up a dose. And if a step up hits hard, clinicians routinely hold the current dose an extra month before climbing again. That is a standard move, not a failure.
How to Calm the Common Side Effects
Most of the fixes are about working with a slower stomach instead of against it. The Mayo Clinic and NIDDK both note that these effects usually lessen with time; your job is to survive the adjustment weeks comfortably.
- Eat smaller meals, and stop at the first sign of fullness. Overshooting fullness is the number one nausea trigger on these drugs.
- Go easy on greasy and fried food. Fat sits longest in a slowed stomach. Bland, low-fat meals digest easiest during dose-increase weeks.
- Drink water all day. Vomiting and diarrhea drain fluids fast, and dehydration is the pathway to the kidney problems described below.
- For constipation: fiber, fluids, and movement first; a clinician can suggest a stool softener if that fails.
- Stay upright after eating, and keep dinner light — reflux and burping are worse when you lie down full.
- Ask about anti-nausea medication. Prescribers commonly add one for rough titration weeks rather than abandoning treatment.
What you eat does more work here than any other single lever, and we break down specific foods, meal sizes, and a sample day in our guide to what to eat on a GLP-1.
Injection-site redness or irritation affects a smaller share of patients and usually passes quickly; rotating sites between the abdomen, thigh, and upper arm helps. If needles themselves are the problem, oral GLP-1 options exist — though the pills cause the same stomach effects, because the mechanism is the drug, not the needle.
Serious GLP-1 Side Effects: What Is Not Normal
A short list of rare problems needs a completely different response than riding it out.
Pancreatitis. Inflammation of the pancreas has been reported with GLP-1 drugs. The warning sign is severe, persistent abdominal pain — often radiating to the back, with or without vomiting — not the mild queasiness of a dose increase. The label says stop the drug and get evaluated promptly if pancreatitis is suspected.
Gallbladder disease. Per the Wegovy prescribing information, gallstones were reported in 1.6% of Wegovy patients versus 0.7% on placebo, and rapid weight loss by any method raises gallstone risk on its own. Pain in the upper-right abdomen, fever, or yellowing skin or eyes means same-day medical care.
Kidney injury. GLP-1 drugs do not attack the kidneys directly; the danger runs through dehydration. Heavy vomiting or diarrhea can drop fluid levels far enough to injure kidneys, which is why the labeling flags acute kidney injury and why fluids matter so much during bad stretches.
Thyroid C-cell tumors — the boxed warning. Semaglutide and tirzepatide carry the FDA’s most serious warning because they caused thyroid C-cell tumors in rodent studies. Whether that translates to humans is unknown, but the drugs are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. A lump in the neck, hoarseness, or trouble swallowing needs evaluation.
Low blood sugar. On its own, a GLP-1 rarely causes hypoglycemia — but combined with insulin or a sulfonylurea, the risk is real, and diabetes medications often need adjusting. People with type 2 diabetes should also report any vision changes, which the semaglutide labeling flags.
Two more notes. Post-marketing reports of ileus — a bowel that stops moving — appear in semaglutide labeling, so constipation that becomes total blockage with bloating and vomiting is an emergency. And tell any surgeon or anesthesiologist that you take a GLP-1: a slowed stomach matters before sedation.
When to Call a Doctor: A Quick Sorting Table
| Symptom | Usually normal | Get medical help |
|---|---|---|
| Nausea | Days after a dose increase, fades within 1–2 weeks | Cannot keep fluids down for 24+ hours |
| Stomach pain | Mild, crampy, comes and goes | Severe, constant, or radiating to your back |
| Constipation | Sluggish but moving; improves with fiber and fluids | No bowel movement for days plus bloating or vomiting |
| Diarrhea | Loose stools for a few days post-increase | Signs of dehydration: dizziness, dark urine, racing heart |
| Injection site | Mild redness that fades in a day or two | Spreading rash, swelling of face or throat, trouble breathing |
| Mood | Normal ups and downs | New depression or thoughts of self-harm — the labeling says report these |
The one-line rule: GLP-1 side effects that are mild, tied to dose changes, and improving are the normal cost of titration. Anything severe, constant, or getting worse is not, and waiting it out is the wrong move.
Do Side Effects Mean the Drug Is Working — or Failing?
Neither. Nausea is not a receipt for weight loss, and its absence is not a defect. The signal that the medication is working is quieter: you get full sooner, food noise drops, and portions shrink without white-knuckle effort. Trial participants lost weight at every level of side-effect severity.
The flip side trips people up around month 4 or 5: the nausea fades and the scale slows at about the same time, and it is easy to conclude the drug “stopped working.” Usually those are two unrelated events — your gut adapted, and your weight loss found its natural pace. In STEP 1, weight loss continued for over a year even as early side effects settled. If your progress genuinely stalls for a month or more, our GLP-1 plateau guide walks through what is normal and what to change.
Compounded GLP-1s Add a Dosing-Error Risk
Everything above describes FDA-approved products tested in trials. Millions of people, though, take compounded semaglutide or tirzepatide from telehealth programs at $99–$449 a month — and compounded versions are not FDA-approved. The FDA says plainly that it has received reports of dosing errors and adverse events involving compounded GLP-1 drugs, some requiring medical attention.
The mechanics explain why. Brand-name pens click to a preset dose; many compounded programs ship a vial and syringe, and drawing 0.25 mg by hand leaves room for a tenfold mistake. Concentrations also vary between pharmacies, so a switch mid-treatment can silently change how much you inject. If you go the compounded route, insist on a provider that names its pharmacy, states the concentration on the label, and walks you through the syringe markings — our ranking of the best weight loss injections tracks exactly which providers do.
Side effects are the toll every GLP-1 charges on the way to results the STEP 1 and SURMOUNT-1 trials measured — about 14.9% and up to 20.9% average weight loss respectively. For most people the toll is a queasy month here and there, managed with smaller meals and patience. Know the short list of symptoms that break the pattern, and you can handle the rest with a bland dinner and a glass of water.